{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-23-000076","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.911573+00:00","generated_at":"2026-06-08T02:29:28.116595+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"vTv Therapeutics approves 1-for-40 reverse stock split to regain Nasdaq compliance","bullets":["Reverse split effective 4:01 PM ET on Nov 20, 2023; post-split trading begins Nov 21.","Ratio 1-for-40 applies equally to Class A and Class B common stock; fractional shares rounded up.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement.","CUSIP for post-split Class A common stock: 91835204; proportionate ownership unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-23-000076","json":"https://secwatch.observer/filing/0001641489-23-000076.json","markdown":"https://secwatch.observer/filing/0001641489-23-000076.md","text":"https://secwatch.observer/filing/0001641489-23-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000076/0001641489-23-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000076/vtvt-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:29:28.116595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}